FBLG FibroBiologics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FBLG

Price (delayed)

$0.9364

Market cap

$35.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.34

Enterprise value

$31.9M

We are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple ...

Highlights
The equity has soared by 118% YoY
FibroBiologics's EPS has surged by 50% YoY and by 43% QoQ
FBLG's quick ratio is up by 10% year-on-year but it is down by 6% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.fibrobiologics.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of FBLG
Market
Shares outstanding
37.74M
Market cap
$35.34M
Enterprise value
$31.9M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$13.74M
Net income
-$11.16M
EBIT
-$11.14M
EBITDA
-$10.57M
Free cash flow
-$12.09M
Per share
EPS
-$0.34
EPS diluted
-$0.34
Free cash flow per share
-$0.37
Book value per share
$0.08
Revenue per share
$0
TBVPS
$0.5
Balance sheet
Total assets
$16.45M
Total liabilities
$13.71M
Debt
$10.55M
Equity
$2.74M
Working capital
$1.5M
Liquidity
Debt to equity
3.86
Current ratio
1.12
Quick ratio
1.1
Net debt/EBITDA
0.32
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-94.5%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-299.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FBLG stock price

How has the FibroBiologics stock price performed over time
Intraday
8.88%
1 week
-9.96%
1 month
-25.68%
1 year
-91.33%
YTD
-53.18%
QTD
4.04%

Financial performance

How have FibroBiologics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.74M
Net income
-$11.16M
Gross margin
N/A
Net margin
N/A
FibroBiologics's operating income has shrunk by 55% YoY and by 10% QoQ
The net income has grown by 37% since the previous quarter and by 32% year-on-year

Growth

What is FibroBiologics's growth rate over time

Valuation

What is FibroBiologics stock price valuation
P/E
N/A
P/B
11.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
FibroBiologics's EPS has surged by 50% YoY and by 43% QoQ
The equity has soared by 118% YoY

Efficiency

How efficient is FibroBiologics business performance
The ROA has soared by 59% YoY and by 43% QoQ

Dividends

What is FBLG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FBLG.

Financial health

How did FibroBiologics financials performed over time
The total assets is 20% greater than the total liabilities
FibroBiologics's total liabilities has surged by 77% QoQ and by 30% YoY
The total assets has surged by 57% since the previous quarter and by 39% year-on-year
The debt to equity has soared by 156% year-on-year
The equity has soared by 118% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.